AxogenAXGN
Market Cap: $571M
About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Employees: 428
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
31,275% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $4K
45% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 33
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
4% more funds holding
Funds holding: 120 [Q1] → 125 (+5) [Q2]
4.39% less ownership
Funds ownership: 85.11% [Q1] → 80.72% (-4.39%) [Q2]
14% less capital invested
Capital invested by funds: $297M [Q1] → $255M (-$41.2M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities David Turkaly 59% 1-year accuracy 16 / 27 met price target | 54%upside $20 | Market Outperform Maintained | 9 Aug 2024 |
Raymond James Jayson Bedford 73% 1-year accuracy 22 / 30 met price target | 0%downside $13 | Outperform Initiated | 1 Jul 2024 |
Canaccord Genuity Caitlin Cronin 45% 1-year accuracy 5 / 11 met price target | 15%upside $15 | Buy Reiterated | 20 Jun 2024 |
Financial journalist opinion
Based on 5 articles about AXGN published over the past 30 days